Study protocol for a non-inferiority trial of cytisine versus nicotine replacement therapy in people motivated to stop smoking

BMC Public Health

Volumn 11, Issue , 2011, Pages

  Walker, Natalie ^a   Howe, Colin ^a   Bullen, Chris ^a   McRobbie, Hayden ^b   Glover, Marewa ^c   Parag, Varsha ^a   Williman, Jonathan ^a   Veale, Reon ^d   Nosa, Vili ^a   Barnes, Joanne ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c Faculty of Medical and Health Sciences School of Population Health   (New Zealand)

^d Quit Group   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALOID; AZOCINE DERIVATIVE; CYTISINE; NICOTINE; NICOTINE GUM; QUINOLIZINE DERIVATIVE;

ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; HUMAN; METHODOLOGY; MOTIVATION; NEW ZEALAND; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SINGLE BLIND PROCEDURE; SMOKING; SMOKING CESSATION; STATISTICS; TREATMENT OUTCOME;

ADULT; ALKALOIDS; AZOCINES; CLINICAL PROTOCOLS; HUMANS; MOTIVATION; NEW ZEALAND; NICOTINE; QUINOLIZINES; SAMPLE SIZE; SINGLE-BLIND METHOD; SMOKING; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS; TREATMENT OUTCOME;

EID: 81355138203     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-11-880     Document Type: Review

References (36)

1. Peto R, Lopez A, Boreham J, Thun M, Mortality from smoking in developed countries 1950-2000 Oxford: Oxford University Press 2 2004
2. Ministry of Health: Looking upstream, Causes of death cross-classified by risk and condition New Zealand 1997 Wellington: Ministry of Health 2004
3. What is the contribution of smoking and socioeconomic position to ethnic inequalities in mortality in New Zealand? Blakely T, Fawcett J, Hunt D, Wilson N, Lancet 2006 368 9529 44 52 10.1016/S0140-6736(06)68813-2 16815379 (Pubitemid 43947179)
4. Mortality in relation to smoking: 50 years' observations on male British doctors. Doll R, Peto R, Boreham J, Sutherland I, BMJ 2004 328 7455 1519 10.1136/bmj.38142.554479.AE 15213107
5. Cost effectiveness analysis of smoking cessation interventions. Shearer J, Shanahan M, Aust N Z J Public Health 2006 30 5 428 434 10.1111/j.1467-842X. 2006.tb00458.x 17073223 (Pubitemid 44614447)
6. Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews, The Cochrane Library. Stead L, Perera R, Bullen C, Mant D, Lancaster T, 2008 1 D000146
7. Antidepressants for smoking cessation. Cochrane Database of Systematic Reviews, The Cochrane Library. Hughes JR, Stead LF, Lancaster T, 2007 1 D000031
8. Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews, The Cochrane Library. Cahill K, Stead LF, Lancaster T, 2011 2 rt. No.: CD006103
9. Ministry of Health, Tobacco use in New Zealand: Key findings from the 2009 New Zealand Tobacco Use Survey Wellington: Ministry of Health 2010
10. Stop-smoking medications: who uses them, who misuses them, and who is misinformed about them? Bansal MA, Cummings KM, Hyland A, Giovino GA, Nicotine Tob Res 2004 6 Suppl 3 303 310 15799593
11. Ministry of Health, New Zealand Tobacco Use Survey 2008 Wellington: Ministry of Health 2009 Quitting results
12. Checklist of dicotyledons naturalised in New Zealand. Webb C, NZ J Botany 1980 18 463 472
13. Godley E, Introducing Kowhai. Styx report Christchurch: Landcare Research 2006
14. Cytisine for smoking cessation: a literature review and a meta-analysis. Etter JF, Arch Intern Med 2006 166 15 1553 1559 10.1001/archinte.166.15.1553 16908787 (Pubitemid 44232362)
15. [Results of the smoking-habit breaking using cytisine (Tabex). I]. Benndorf S, Kempe G, Scharfenberg G, Wendekamm R, Winkelvoss E, Dtsch Gesundheitsw 1968 23 44 2092 2096 5730918
16. A double-blind, randomised, placebo-controlled trial of cytisine for smoking cessation in medium-dependent workers. Vinnikov D, Brimkulov N, Burjubaeva A, J Smoking Cessation 2008 3 1 57 62
17. Placebo-controlled trial of cytisine for smoking cessation. West R, Zatonski W, Cedzynska M, Lewandowska D, Pazik J, Aveyard P, Stapleton J, New Engl J Med 2011 365 13 1193 1200 10.1056/NEJMoa1102035 21991893
18. Fatal cytisine intoxication and analysis of biological samples with LC-MS/MS. Musshoff F, Madea B, Forensic Sci Int 2009 186 1-3 1 4 10.1016/j.forsciint.2009.01.011 19217730
19. Cytisine's potential to be used as traditional healing method to help indigenous people stop smoking: A qualitative study with Maori. Thompson-Evans T, Glover M, Walker N, Nicotine Tob Res 2011 13 5 353 360 10.1093/ntr/ntr002 21385905
20. Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic efficacy. Tutka P, Zatonski W, Pharmacol Rep 2006 58 6 777 798 17220536 (Pubitemid 46117730)
21. [Cytisine (Tabex) as a pharmaceutical aid in stopping smoking]. Scharfenberg G, Benndorf S, Kempe G, Dtsch Gesundheitsw 1971 26 10 463 465 4930772
22. [Medical support of nicotine withdrawal. Report on a double blind trial in over 5000 smokers]. Schmidt F, MMW Munch Med Wochenschr 1974 116 11 557 564 4208732
23. [Breaking the smoking habit using cytisine containing "Tabex" tablets]. Paun D, Franze J, Dtsch Gesundheitsw 1968 23 44 2088 2091 5730917
24. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO, Br J Addict 1991 86 9 1119 1127 10.1111/j.1360-0443.1991.tb01879.x 1932883
25. Confirmatory factor analysis and reliability of the modified cigarette evaluation questionnaire. Cappelleri J, Bushmakin A, Baker C, Merikle E, Olufade A, Gilbert D, Addictive Behav 2007 32 912 923 10.1016/j.addbeh.2006.06.028 (Pubitemid 46282288)
26. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Aubin H-J, Bobak A, Britton J, Oncken C, Billing C, Gong J, Williams K, Reeves K, Thorax 2008 63 717 724 10.1136/thx.2007.090647 18263663
27. Evaluation of the mood and physical symptoms scale (MPSS) to assess cigarette withdrawal. West R, Hajek P, Psychopharmacology (Berl) 2004 177 1-2 195 199 10.1007/s00213-004-1923-6 (Pubitemid 40109930)
28. Varenicline, an nictotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Steensland P, Simms J, Holgate J, Richards J, Barlett S, PNAS 2007 104 30 12518 12523 10.1073/pnas.0705368104 17626178 (Pubitemid 47206170)
29. Varenicline reduces alcohol self-administration in heavy drinking smokers. McKee S, Harrison E, O'Malley S, Krishnan-Sarin S, Shi J, Tetrault J, Picciotto M, Petrakis I, Estevez N, Balchunas E, Biol Psychiatry 2009 66 2 185 190 10.1016/j.biopsych.2009.01.029 19249750
30. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinkers. Bush K, Kivlahan D, McDonell M, Fihn S, Bradley K, Arch Intern Med 1998 158 1789 1795 10.1001/archinte.158.16.1789 9738608 (Pubitemid 28421422)
31. Gravitas Research and Strategy Limited, New Quitline service evaluation-longitudinal survey: Results from three-week and six-month follow-up survey Wellington: The Quit Group 2009
32. Pre-cessation nicotine replacement therapy: pragmatic randomized trial. Bullen C, Howe C, Lin RB, Grigg M, Laugesen M, McRobbie H, Glover M, Walker N, Wallace-Bell M, Whittaker R, Rodgers A, Addiction 2010 105 8 1474 1483 10.1111/j.1360-0443.2010.02989.x 20528810
33. Does improved access and greater choice of nicotine replacement therapy affect smoking cessation success? Findings from a randomised controlled trial. Walker N, Howe C, Grigg M, Bullen C, Glover M, Vander Hoorn S, McRobbie H, Laugesen M, Whittaker R, Rodgers A, Addiction 2011 106 6 1176 1185 10.1111/j.1360-0443.2011.03419.x 21371155
34. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ, JAMA 2006 295 10 1152 1160 10.1001/jama.295.10.1152 16522836 (Pubitemid 43352345)
35. Non-inferiority trials: design concepts and issues-the encounters of academic consultants in statistics. D'Agostino RB, Massaro JM, Sullivan LM, Stat Med 2003 22 2 169 186 12520555 (Pubitemid 36163579)
36. Biochemical verification of tobacco use and cessation. SRNT Subcommittee on Biochemical Verification, Nicotine Tob Res 2002 4 2 149 159 10.1080/14622200210123581 12028847 (Pubitemid 34679841)